Adaptive Radiation Dose Escalation for Non-Small Cell Lung Cancer
(PET-BOOST Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive conventional chemoradiotherapy or chemoradiotherapy with a radiation (RT) integrated boost. All patients will receive a fludeoxyglucose-positron emission tomography (FDG-PET) scan within two weeks prior to starting treatment. The primary outcome is to determine if dose escalation to metabolically active tumor subvolumes will reduce local-regional failure rate at 2 years.
Are You a Good Fit for This Trial?
Adults with locally advanced non-small cell lung cancer who can undergo chemoradiotherapy, have a certain level of physical fitness (ECOG status 0-2), and tumors visible on scans. Excluded are those with poor respiratory function, significant recent weight loss, inadequate bone marrow reserve, other active cancers, severe heart or lung conditions, liver issues, pregnancy, or AIDS.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive chemoradiotherapy with or without an integrated boost dose, including concurrent cisplatin and etoposide chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of local-regional failure rate and quality of life
What Are the Treatments Tested in This Trial?
Interventions
- Chemoradiotherapy
- Chemoradiotherapy with Integrated Boost Dose
Find a Clinic Near You
Who Is Running the Clinical Trial?
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre OR Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's
Lead Sponsor
Lawson Health Research Institute
Lead Sponsor